sirolimus and Paronychia

sirolimus has been researched along with Paronychia* in 2 studies

Other Studies

2 other study(ies) available for sirolimus and Paronychia

ArticleYear
[Adverse cutaneous effects and quality of life in patients treated with mTOR inhibitors for renal carcinoma].
    Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:5

    Mammalian target of rapamycine (mTOR) inhibitors are being increasingly prescribed as antitumoural drugs, and associated adverse cutaneous effects are frequent but poorly described. The aim of this study was to describe such adverse effects and to assess the quality of life of patients experiencing them.. Over a period of 18 months, 18 patients treated with mTOR inhibitors for renal carcinoma were included and 77 dermatological examinations performed. Wherever a cutaneous adverse event was present, quality of life was evaluated using the Skindex 30 questionnaire.. Fifteen of the 18 patients included presented adverse cutaneous events, consisting of buccal ulcers (61.1%), xerosis (55.5%), distal onycholysis (50%), acneiform eruption (38.8%), paronychia (22.2%) and pruritus (22.2%). Buccal ulcerations and perionyxis had an especially marked impact on quality of life, which was greatest in terms of physical score (19%), followed by emotional (9%) and functional (6%) scores.. Cutaneous adverse effects of mTOR inhibitors are frequent and have a considerable impact on quality of life, particularly as regards physical scores. Dermatological examination appears useful to allow early management of cutaneous adverse effects and improve the quality of life of these patients.

    Topics: Acneiform Eruptions; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Emotions; Everolimus; Female; Humans; Ichthyosis; Kidney Neoplasms; Male; Middle Aged; Onycholysis; Paronychia; Prospective Studies; Pruritus; Quality of Life; Severity of Illness Index; Sirolimus; Stomatitis, Aphthous; TOR Serine-Threonine Kinases

2013
Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors.
    Acta dermato-venereologica, 2011, Volume: 91, Issue:5

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Everolimus; Female; Granuloma, Pyogenic; Humans; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases

2011